JP Morgan Chase’s Epizyme, Inc EPZM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-5,001
| Closed | -$7K | – | 7162 |
|
|
2022
Q2 | $7K | Sell |
5,001
-241,909
| -98% | -$178K | ﹤0.01% | 6114 |
|
|
2022
Q1 | $284K | Buy |
246,910
+40,142
| +19% | +$65.4K | ﹤0.01% | 4996 |
|
|
2021
Q4 | $517K | Sell |
206,768
-64,653
| -24% | -$254K | ﹤0.01% | 4800 |
|
|
2021
Q3 | $1.39M | Buy |
271,421
+39,230
| +17% | +$238K | ﹤0.01% | 4064 |
|
|
2021
Q2 | $1.93M | Sell |
232,191
-11,047
| -5% | -$93.1K | ﹤0.01% | 3821 |
|
|
2021
Q1 | $2.12M | Sell |
243,238
-23,775
| -9% | -$246K | ﹤0.01% | 3687 |
|
|
2020
Q4 | $2.9M | Sell |
267,013
-13,563
| -5% | -$167K | ﹤0.01% | 3224 |
|
|
2020
Q3 | $3.38M | Sell |
280,576
-131,846
| -32% | -$1.77M | ﹤0.01% | 2870 |
|
|
2020
Q2 | $6.62M | Buy |
412,422
+126,138
| +44% | +$2.2M | ﹤0.01% | 2241 |
|
|
2020
Q1 | $4.44M | Sell |
286,284
-153,119
| -35% | -$3.29M | ﹤0.01% | 2357 |
|
|
2019
Q4 | $10.8M | Sell |
439,403
-39,481
| -8% | -$586K | ﹤0.01% | 2053 |
|
|
2019
Q3 | $4.94M | Sell |
478,884
-49,527
| -9% | -$625K | ﹤0.01% | 2709 |
|
|
2019
Q2 | $6.45M | Buy |
528,411
+79,251
| +18% | +$1.02M | ﹤0.01% | 2441 |
|
|
2019
Q1 | $5.57M | Buy |
449,160
+71,917
| +19% | +$804K | ﹤0.01% | 2504 |
|
|
2018
Q4 | $2.32M | Buy |
377,243
+14,400
| +4% | +$110K | ﹤0.01% | 3171 |
|
|
2018
Q3 | $3.85M | Buy |
362,843
+230,393
| +174% | +$2.63M | ﹤0.01% | 2952 |
|
|
2018
Q2 | $1.79M | Sell |
132,450
-62,962
| -32% | -$980K | ﹤0.01% | 3491 |
|
|
2018
Q1 | $3.47M | Buy |
195,412
+184,843
| +1,749% | +$3.12M | ﹤0.01% | 2872 |
|
|
2017
Q4 | $133K | Sell |
10,569
-147,831
| -93% | -$2.15M | ﹤0.01% | 4559 |
|
|
2017
Q3 | $2.88M | Sell |
158,400
-2,800
| -2% | -$42.7K | ﹤0.01% | 2934 |
|
|
2017
Q2 | $2.43M | Sell |
161,200
-26,550
| -14% | -$401K | ﹤0.01% | 2924 |
|
|
2017
Q1 | $3.22M | Sell |
187,750
-21,650
| -10% | -$288K | ﹤0.01% | 2728 |
|
|
2016
Q4 | $2.53M | Sell |
209,400
-15,200
| -7% | -$159K | ﹤0.01% | 2915 |
|
|
2016
Q3 | $2.21M | Buy |
224,600
+444
| +0.2% | +$4.05K | ﹤0.01% | 2738 |
|
|
2016
Q2 | $2.29M | Buy |
224,156
+70,500
| +46% | +$786K | ﹤0.01% | 2735 |
|
|
2016
Q1 | $1.86M | Buy |
153,656
+130,044
| +551% | +$1.32M | ﹤0.01% | 2740 |
|
|
2015
Q4 | $378K | Buy |
23,612
+712
| +3% | +$10.6K | ﹤0.01% | 3487 |
|
|
2015
Q3 | $295K | Sell |
22,900
-8,575
| -27% | -$173K | ﹤0.01% | 3585 |
|
|
2015
Q2 | $756K | Sell |
31,475
-31,052
| -50% | -$598K | ﹤0.01% | 3410 |
|
|
2015
Q1 | $1.18M | Buy |
62,527
+5,902
| +10% | +$122K | ﹤0.01% | 3151 |
|
|
2014
Q4 | $1.07M | Sell |
56,625
-444,227
| -89% | -$10.4M | ﹤0.01% | 3308 |
|
|
2014
Q3 | $13.6M | Buy |
500,852
+500
| +0.1% | +$15.5K | ﹤0.01% | 1706 |
|
|
2014
Q2 | $15.6M | Sell |
500,352
-93,889
| -16% | -$2.21M | ﹤0.01% | 1490 |
|
|
2014
Q1 | $13.5M | Buy |
+594,241
| New | +$18M | ﹤0.01% | 1554 |
|
Other funds holding EPZM
JP Morgan Chase's EPZM Position: Q3 2022 in Review
JP Morgan Chase sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 5,001 shares — an estimated $7K sold.
JP Morgan Chase first reported a position in EPZM in Q1 2014 and held it in 34 quarters. The position peaked at $15.6M in Q2 2014. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.
- JP Morgan Chase reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
- JP Morgan Chase sold 5,001 Epizyme, Inc shares in Q3 2022, an estimated $7K.
- JP Morgan Chase first reported a position in Epizyme, Inc in Q1 2014 and held it in 34 quarters.
- JP Morgan Chase's Epizyme, Inc position peaked at $15.6M in Q2 2014.
- 0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.
Based on JP Morgan Chase's 13F filing for Q3 2022, filed 14 Nov 2022.